Microbiome-Based Diagnostic and Therapeutic System for Endocrine Conditions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for characterizing endocrine system conditions and providing tailored therapies based on microbiome analysis are limited by technological constraints, failing to effectively diagnose and treat conditions such as thyroid disorders, diabetes, and hormonal imbalances due to inadequate characterization of microbiome composition and functional diversity.
Innovation Solution
A method and system that involves receiving biological samples from a population, characterizing microbiome composition and functional features, generating datasets, and transforming these into characterization models to diagnose endocrine system conditions and provide personalized therapeutic measures, including probiotic, phage-based, and small-molecule therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If comprehensive human microbiome characterization is pursued, then diagnostic and therapeutic capabilities are improved, but complexity of analysis and data interpretation increases
Solution Approach 1:
The patent segments the comprehensive microbiome data into discrete operational taxonomic units (OTUs) and functional categories. This segmentation allows complex microbiome compositions to be broken down into manageable, analyzable units that can be individually assessed for diagnostic purposes, thereby improving diagnostic capability while managing analytical complexity.
Solution Approach 2:
The patent introduces computational algorithms and bioinformatics tools as intermediaries between raw microbiome sequencing data and clinical interpretation. These intermediary systems process, normalize, and interpret the complex data, enabling accurate diagnostic capabilities without requiring direct human analysis of the full complexity of the data.
2Reliability
If microbiome-based therapeutics are developed, then treatment efficacy for endocrine conditions is improved, but regulatory and safety challenges increase
Solution Approach 1:
The patent establishes specific parameter thresholds and criteria for microbiome-based therapeutics, including standardized measures of treatment efficacy and safety endpoints. By defining clear parameter changes that indicate therapeutic success or safety concerns, the patent simplifies regulatory assessment while maintaining high treatment efficacy standards.
Solution Approach 2:
The patent incorporates feedback mechanisms through standardized monitoring and reporting systems that track treatment efficacy and safety outcomes. This feedback loop enables regulators to assess therapeutic performance systematically, reducing regulatory complexity by providing structured data for evaluation while ensuring high treatment reliability.
3Measurement precision
If advanced computational tools are utilized, then data analysis accuracy is improved, but computational resource requirements increase
Solution Approach 1:
The patent employs partial action by implementing tiered computational analysis that applies increasingly sophisticated algorithms only when necessary. Routine microbiome data receives streamlined analysis, while complex cases trigger more resource-intensive advanced computational tools, thereby maintaining high accuracy for critical analyses while reducing overall computational resource consumption.
Data Source
AI summary
A method for at least one of characterizing, diagnosing, and treating an endocrine system condition in at least a subject, the method comprising: receiving an aggregate set of biological samples from a population of subjects; generating at least one of a microbiome composition dataset and a microbiome functional diversity dataset for the population of subjects; generating a characterization of the endocrine system condition based upon features extracted from at least one of the microbiome composition dataset and the microbiome functional diversity dataset; based upon the characterization, generating a therapy model configured to correct the endocrine system condition; and at an output device associated with the subject, promoting a therapy to the subject based upon the characterization and the therapy model.